{"entity":{"id":"nct00022282","kind":"trial","name":"AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma","aka":[],"tldr":"A phase 2 trial of Shark cartilage in Multiple myeloma, run by AEterna Zentaris, completed.","summary":"AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT00022282 by AEterna Zentaris, started 2001-04 and reaching its primary completion in 2007-03. Interventions recorded: shark cartilage extract AE-941. Conditions recorded: Multiple Myeloma and Plasma Cell Neoplasm.\n\nLinked to the technology Shark cartilage because the registry names it (\"shark cartilage\") among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT00022282","url":"https://clinicaltrials.gov/study/NCT00022282"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["shark-cartilage"],"targets":[],"drugs":[],"companies":["aeterna-zentaris"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00022282","phase":"2","setting":"Neovastat (AE-941) in Refractory and Early Relapse Multiple Myeloma Patients","sponsor":"AEterna Zentaris","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00022282/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"shark-cartilage","kind":"technology","name":"Shark cartilage (AE-941, Neovastat)","route":"/technologies/shark-cartilage/"}],"company":[{"id":"aeterna-zentaris","kind":"company","name":"Aeterna Zentaris","route":"/companies/aeterna-zentaris/"}]}}